Cellectar Biosciences, Inc.

NASDAQ:CLRB

2.13 (USD) • At close September 13, 2024
Bedrijfsnaam Cellectar Biosciences, Inc.
Symbool CLRB
Munteenheid USD
Prijs 2.13
Beurswaarde 76,358,157
Dividendpercentage 0%
52-weken bereik 1.82 - 4.45
Industrie Biotechnology
Sector Healthcare
CEO Mr. James V. Caruso
Website https://www.cellectar.com

An error occurred while fetching data.

Over Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and

Vergelijkbare Aandelen

Aytu BioPharma, Inc. logo

Aytu BioPharma, Inc.

AYTU

2.58 USD

Sio Gene Therapies Inc. logo

Sio Gene Therapies Inc.

SIOX

0.415 USD

Landos Biopharma, Inc. logo

Landos Biopharma, Inc.

LABP

22.93 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)